Related Experiment Video
Updated: Oct 11, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Side Effects of Brolucizumab.
Tahmineh Motevasseli1,2,3, Saeed Mohammadi4,5, Fatemeh Abdi6
1Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Brolucizumab, a new anti-vascular endothelial growth factor (anti-VEGF) therapy for wet age-related macular degeneration, shows promise but carries risks. This review examines brolucizumab
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Age-related macular degeneration (AMD) and subretinal neovascularization cause vision loss.
- Anti-vascular endothelial growth factor (anti-VEGF) therapies have revolutionized retinal disease treatment.
- Established anti-VEGF agents include pegaptanib, ranibizumab, aflibercept, and bevacizumab.
Purpose of the Study:
- To review the reported side effects of brolucizumab, a novel anti-VEGF agent.
- To inform clinicians about potential adverse events associated with brolucizumab therapy.
- To provide a comprehensive overview of brolucizumab's safety profile in managing wet AMD.
Main Methods:
- Conducted a literature search using PubMed and Scopus.
- Included all article types in the review.
- Focused on reported side effects of brolucizumab.
Main Results:
- Brolucizumab, approved in late 2019, is a single-chain fragment variable antibody targeting VEGF-A.
- It is suggested to offer enhanced tissue penetration compared to other anti-VEGF drugs.
- A significant reported side effect is occlusive retinal vasculitis, not observed with other anti-VEGF medications.
Conclusions:
- Brolucizumab offers a new treatment option for wet AMD with potential benefits.
- Clinicians must be aware of and manage serious side effects, particularly retinal vasculitis.
- Understanding brolucizumab's safety profile is crucial for patient management in retinal diseases.
More Related Videos
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Therapeutic Drug Monitoring: Affecting Factors
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms: